Osteochondrosis is a family of orthopedic diseases of the joint that occur in children, adolescents and rapidly growing animals, particularly pigs, horses, dogs, and broiler chickens. They are characterized by interruption of the blood supply of a bone, in particular to the epiphysis, followed by localized bony necrosis, and later, regrowth of the bone. This disorder is defined as a focal disturbance of endochondral ossification and is regarded as having a multifactorial cause, so no one thing accounts for all aspects of this disease.Osteochondrosis is a developmental disease. It usually occurs in an early stage of life. It has personified features as focal chondronecrosis and confinement of growth cartilage due to a failing of endochondral ossification. Fissures can develop from lesions over the top articular cartilage and form a cartilage flap and an osteochondral fragment. It is diagnosed as osteochondritis dissecans. In animals
In dogs osteochondrosis is seen in elbow, shoulder, knee, and ankle joints. Elbow osteochondrosis is also known as "elbow dysplasia". There are three types of elbow dysplasia:  fragmented medial coronoid process, ununited anconeal process and Osteochondritis dissecans of the medial humeral condyle. Breeds that have the predisposition to these are Basset Hound, Labrador, Golden Retriever, and Rottweiler. Other breeds can also be diagnosed with this condition but it is not common.One of the leading factors to some elbow osteochondrosis is that the radius and ulna are growing at different rates.
By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of micturition, urgency and incontinence episodes. Because of a long elimination half life, a once-a-day dose can offer 24-hour control of the urinary bladder smooth muscle tone. Pharmacokinetics
Peak plasma concentrations are reached three to eight hours after absorption from the gut. In the bloodstream, 98% of the substance are bound to plasma proteins, mainly acidic ones. Metabolism is mediated by the liver enzyme CYP3A4 and possibly others. There is one known active metabolite, 4R-hydroxysolifenacin, and three inactive ones, the N-glucuronide, the N-oxide and the 4R-hydroxy-N-oxide. The elimination half-life is 45 to 68 hours. 69% of the substance, both in its original form and as metabolites, are excreted renally and 23% via the feces. Chemistry
Like other anticholinergics, solifenacin is an ester of a carboxylic acid containing (at least) an aromatic ring with an alcohol containing a nitrogen atom. While in the prototype anticholinergic atropine the bicyclic ring is tropane, solifenacin replaces it with quinuclidine. The free base is a yellow oil, while the salt solifenacin succinate forms yellowish crystals. History
The compound was studied using animal models by the Yamanouchi Pharmaceutical Co., Ltd. of Tokyo, Japan.